...
首页> 外文期刊>Journal of cardiology >Neutrophil gelatinase-associated lipocalin (NGAL) in heart transplant recipients after conversion to everolimus therapy
【24h】

Neutrophil gelatinase-associated lipocalin (NGAL) in heart transplant recipients after conversion to everolimus therapy

机译:改用依维莫司治疗后心脏移植受者的中性粒细胞明胶酶相关脂质运载蛋白(NGAL)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Due to the lack of nephrotoxic activity, proliferation signal inhibitors (PSI) such as everolimus are recommended for immunosuppression after heart transplantation, but the assessment of renal function in patients receiving PSI has led to conflicting results. We examined renal integrity and function using neutrophil gelatinase-associated lipocalin (NGAL) and conventional markers [plasma creatinine, cystatin C, urine albumin, alpha(1)-microglobulin (alpha M-1)] in heart transplant patients, who underwent conversion to everolimus due to allograft vasculopathy, graft rejection episodes, or renal function deterioration, and in patients maintained on calcineurin inhibitors (CNI).
机译:背景:由于缺乏肾毒性活性,建议在心脏移植后建议使用依维莫司等增殖信号抑制剂(PSI)进行免疫抑制,但是接受PSI的患者对肾功能的评估导致了相互矛盾的结果。我们在心脏移植患者中使用中性粒细胞明胶酶相关脂质运载蛋白(NGAL)和常规标记[血浆肌酐,胱抑素C,尿白蛋白,α(1)-微球蛋白(alpha M-1)]检查了肾脏的完整性和功能。因同种异体血管病变,移植排斥反应或肾功能恶化引起的依维莫司,以及使用钙调神经磷酸酶抑制剂(CNI)维持的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号